SC
CRBP icon

Stempoint Capital’s Corbus Pharmaceuticals CRBP Stock Holding History

Stempoint Capital’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-101,479
Closed -$4.59M – 57
2024
Q2 		$4.59M Buy
+101,479
New +$4.27M 1.35% 25

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Stempoint Capital's CRBP Position: Q3 2024 in Review

Stempoint Capital sold out of Corbus Pharmaceuticals (CRBP) in Q3 2024, closing a stake of 101,479 shares — an estimated $4.59M sold.

Stempoint Capital first reported a position in CRBP in Q2 2024 and held it in 1 quarter. The position peaked at $4.59M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q3 2024.

  • Stempoint Capital reported no remaining Corbus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Stempoint Capital sold 101,479 Corbus Pharmaceuticals shares in Q3 2024, an estimated $4.59M.
  • Stempoint Capital first reported a position in Corbus Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Stempoint Capital's Corbus Pharmaceuticals position peaked at $4.59M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2024.

Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.